Merrill maintains Myriad at buy

Myriad Genetics Inc. was kept at buy by Merrill Lynch analyst David Munno. The analyst believes Myriad's Flurizan is one of the most promising late-stage Alzheimer's drugs in development, with a solid safety profile for long-term use as well as potential efficacy in combo with approved drugs. While the drug represents a source of significant upside for Myriad, investors should focus on the company's core diagnostics business. Shares of the Salt Lake City biopharmaceutical company were up 5 cents, or 0.20%, at $24.91. (Nasdaq: MYGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.